Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer
Abstract
:1. Introduction
2. Results
2.1. Baseline Characteristics of the Study Patients
2.2. Difference between Good and Poor Responders
2.3. Difference between Baseline and Cycle1
3. Discussion
4. Materials and Methods
4.1. Study Ethics
4.2. Clinical Procedure
4.3. Magnetic Resonance Imaging
4.4. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Torrisi, R.; Marrazzo, E.; Agostinetto, E.; De Sanctis, R.; Losurdo, A.; Masci, G.; Tinterri, C.; Santoro, A. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what? Crit. Rev. Oncol. Hematol. 2021, 160, 103280. [Google Scholar] [CrossRef] [PubMed]
- Banys-Paluchowski, M.; Gasparri, M.L.; de Boniface, J.; Gentilini, O.; Stickeler, E.; Hartmann, S.; Thill, M.; Rubio, I.T.; Di Micco, R.; Bonci, E.-A.; et al. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. Cancers 2021, 13, 1565. [Google Scholar] [CrossRef] [PubMed]
- Potter, D.A.; Herrera-Ponzanelli, C.A.; Hinojosa, D.; Castillo, R.; Hernandez-Cruz, I.; Arrieta, V.A.; Franklin, M.J.; Yee, D. Recent advances in neoadjuvant therapy for breast cancer. Fac. Rev. 2021, 10, 2. [Google Scholar] [CrossRef]
- Kim, M.M.; Allen, P.; Gonzalez-Angulo, A.M.; Woodward, W.A.; Meric-Bernstam, F.; Buzdar, A.U.; Hunt, K.K.; Kuerer, H.M.; Litton, J.K.; Hortobagyi, G.N.; et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann. Oncol. 2013, 24, 1999–2004. [Google Scholar] [CrossRef] [PubMed]
- Henry, N.L.; Kim, S.; Hays, R.D.; Diniz, M.A.; Tighiouart, M.; Gresham, G.; Luu, M.; Cecchini, R.S.; Yothers, G.; Rogatko, A.; et al. Toxicity index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30. Npj Breast Cancer 2022, 8, 123. [Google Scholar] [CrossRef]
- Contorno, S.; Darienzo, R.E.; Tannenbaum, R. Evaluation of aromatic amino acids as potential biomarkers in breast cancer by Raman spectroscopy analysis. Sci. Rep. 2021, 11, 1698. [Google Scholar] [CrossRef]
- Cheung, S.M.; Husain, E.; Mallikourti, V.; Masannat, Y.; Heys, S.; He, J. Intra-tumoural lipid composition and lymphovascular invasion in breast cancer via non-invasive magnetic resonance spectroscopy. Eur. Radiol. 2021, 31, 3703–3711. [Google Scholar] [CrossRef]
- Cheung, S.M.; Husain, E.; Masannat, Y.; Miller, I.D.; Wahle, K.; Heys, S.D.; He, J. Lactate concentration in breast cancer using advanced magnetic resonance spectroscopy. Br. J. Cancer 2020, 123, 261–267. [Google Scholar] [CrossRef]
- Cheung, S.M.; Wu, W.; Senn, N.; Sharma, R.; McGoldrick, T.; Gagliardi, T.; Husain, E.; Masannat, Y.; He, J. Towards detection of early response in neoadjuvant chemotherapy of breast cancer using Bayesian intravoxel incoherent motion. Front. Oncol. 2023, 13, 1277556. [Google Scholar] [CrossRef]
- Liu, M.; Guo, X.; Wang, S.; Jin, M.; Wang, Y.; Li, J.; Liu, J. BOLD-MRI of breast invasive ductal carcinoma: Correlation of R2* value and the expression of HIF-1alpha. Eur. Radiol. 2013, 23, 3221–3227. [Google Scholar] [CrossRef]
- Wong, C.C.-L.; Gilkes, D.M.; Zhang, H.; Chen, J.; Wei, H.; Chaturvedi, P.; Fraley, S.I.; Wong, C.-M.; Khoo, U.-S.; Ng, I.O.-L.; et al. Hypoxia-inducible factor 1 is a master regulator of breast metastatic niche formation. Proc. Natl. Acad. Sci. USA 2011, 108, 16369–16374. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.Y.; Attané, C.; Milhas, D.; Dirat, B.; Dauvillier, S.; Guerard, A.; Gilhodes, J.; Lazar, I.; Alet, N.; Laurent, V.; et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight 2017, 2, e87489. [Google Scholar] [CrossRef] [PubMed]
- Chan, K.S.; Cheung, S.M.; Senn, N.; Husain, E.; Masannat, Y.; Heys, S.; He, J. Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer. BMC Cancer 2022, 22, 285. [Google Scholar] [CrossRef] [PubMed]
- Ramadan, S.; Arm, J.; Silcock, J.; Santamaria, G.; Buck, J.; Roy, M.; Leong, K.M.; Lau, P.; Clark, D.; Malycha, P.; et al. Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations. Radiology 2015, 275, 675–682. [Google Scholar] [CrossRef]
- Vogel, A.; Brunner, J.S.; Hajto, A.; Sharif, O.; Schabbauer, G. Lipid scavenging macrophages and inflammation. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2022, 1867, 159066. [Google Scholar] [CrossRef]
- Ramos, R.N.; Rodriguez, C.; Hubert, M.; Ardin, M.; Treilleux, I.; Ries, C.H.; Lavergne, E.; Chabaud, S.; Colombe, A.; Trédan, O.; et al. CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clin. Transl. Immunol. 2020, 9, e1108. [Google Scholar] [CrossRef]
- Cheung, S.M.; Chan, K.S.; Zhou, W.; Husain, E.; Gagliardi, T.; Masannat, Y.; He, J. Spatial heterogeneity of peri-tumoural lipid composition in postmenopausal patients with oestrogen receptor positive breast cancer. Sci. Rep. 2024, 14, 4699. [Google Scholar]
- Bracci, L.; Schiavoni, G.; Sistigu, A.; Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014, 21, 15–25. [Google Scholar] [CrossRef]
- Galluzzi, L.; Buque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 2015, 28, 690–714. [Google Scholar] [CrossRef]
- Bae, M.S.; Shin, S.U.; Ryu, H.S.; Han, W.; Im, S.-A.; Park, I.-A.; Noh, D.-Y.; Moon, W.K. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival. Radiology 2016, 281, 392–400. [Google Scholar] [CrossRef]
- Cheon, H.; Kim, H.J.; Kim, T.H.; Ryeom, H.-K.; Lee, J.; Kim, G.C.; Yuk, J.-S.; Kim, W.H. Invasive Breast Cancer: Prognostic Value of Peritumoral Edema Identified at Preoperative MR Imaging. Radiology 2018, 287, 68–75. [Google Scholar] [CrossRef] [PubMed]
- Costantini, M.; Belli, P.; Distefano, D.; Bufi, E.; Matteo, M.D.; Rinaldi, P.; Giuliani, M.; Petrone, G.; Magno, S.; Bonomo, L. Magnetic resonance imaging features in triple-negative breast cancer: Comparison with luminal and HER2-overexpressing tumors. Clin. Breast Cancer 2012, 12, 331–339. [Google Scholar] [CrossRef] [PubMed]
- Taylor, C.T.; Colgan, S.P. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat. Rev. Immunol. 2017, 17, 774–785. [Google Scholar] [CrossRef]
- Saito, R.d.F.; Andrade, L.N.d.S.; Bustos, S.O.; Chammas, R. Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells. Front. Immunol. 2022, 13, 768606. [Google Scholar] [CrossRef]
- Gartung, A.; Yang, J.; Sukhatme, V.P.; Bielenberg, D.R.; Fernandes, D.; Chang, J.; Schmidt, B.A.; Hwang, S.H.; Zurakowski, D.; Huang, S.; et al. Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. Proc. Natl. Acad. Sci. USA 2019, 116, 1698–1703. [Google Scholar] [CrossRef]
- Maisel, B.A.; Yi, M.; Peck, A.R.; Sun, Y.; Hooke, J.A.; Kovatich, A.J.; Shriver, C.D.; Hu, H.; Nevalainen, M.T.; Tanaka, T.; et al. Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer. Cancers 2022, 14, 308. [Google Scholar] [CrossRef]
- Broadfield, L.A.; Pane, A.A.; Talebi, A.; Swinnen, J.V.; Fendt, S. Lipid metabolism in cancer: New perspectives and emerging mechanisms. Dev. Cell 2021, 56, 1363–1393. [Google Scholar] [CrossRef] [PubMed]
- Henze, A.; Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Investig. 2016, 126, 3672–3679. [Google Scholar] [CrossRef]
- Koundouros, N.; Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br. J. Cancer 2020, 122, 4–22. [Google Scholar] [CrossRef]
- Yu, X.-H.; Ren, X.-H.; Liang, X.-H.; Tang, Y.-L. Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review). Mol. Med. Rep. 2018, 18, 5307–5316. [Google Scholar] [CrossRef]
- Zaidi, N.E.; Shazali, N.A.H.; Leow, T.C.; Osman, M.A.; Ibrahim, K.; Rahman, N.M.A.N.A. Crosstalk between fatty acid metabolism and tumour-associated macrophages in cancer progression. Biomedicine 2022, 12, 9–19. [Google Scholar] [CrossRef] [PubMed]
- Huang, S.C.-C.; Everts, B.; Ivanova, Y.; O’Sullivan, D.; Nascimento, M.; Smith, A.M.; Beatty, W.; Love-Gregory, L.; Lam, W.Y.; O’Neill, C.M.; et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat. Immunol. 2014, 15, 846–855. [Google Scholar] [CrossRef] [PubMed]
- Nomura, M.; Liu, J.; Rovira, I.I.; Gonzalez-Hurtado, E.; Lee, J.; Wolfgang, M.J.; Finkel, T. Fatty acid oxidation in macrophage polarization. Nat. Immunol. 2016, 17, 216–217. [Google Scholar] [CrossRef]
- Serhan, C.N.; Chiang, N.; Dalli, J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin. Immunol. 2015, 27, 200–215. [Google Scholar] [CrossRef] [PubMed]
- Szekely, B.; Bossuyt, V.; Li, X.; Wali, V.B.; Patwardhan, G.A.; Frederick, C.; Silber, A.; Park, T.; Harigopal, M.; Pelekanou, V.; et al. Immunological differences between primary and metastatic breast cancer. Ann. Oncol. 2018, 29, 2232–2239. [Google Scholar] [CrossRef]
- Rysman, E.; Brusselmans, K.; Scheys, K.; Timmermans, L.; Derua, R.; Munck, S.; Van Veldhoven, P.P.; Waltregny, D.; Daniëls, V.W.; Machiels, J.; et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70, 8117–8126. [Google Scholar] [CrossRef]
- Seo, M.; Ryu, J.K.; Jahng, G.-H.; Sohn, Y.-M.; Rhee, S.J.; Oh, J.-H.; Won, K.-Y. Estimation of T2* Relaxation Time of Breast Cancer: Correlation with Clinical, Imaging and Pathological Features. Korean J. Radiol. 2017, 18, 238–248. [Google Scholar] [CrossRef]
- Hinshaw, D.C.; Hanna, A.; Lama-Sherpa, T.; Metge, B.; Kammerud, S.C.; Benavides, G.A.; Kumar, A.; Alsheikh, H.A.; Mota, M.; Chen, D.; et al. Hedgehog signaling regulates metabolism and polarization of mammary tumor-associated macrophages. Cancer Res. 2021, 81, 5425–5437. [Google Scholar] [CrossRef]
- Shao, N.; Qiu, H.; Liu, J.; Xiao, D.; Zhao, J.; Chen, C.; Wan, J.; Guo, M.; Liang, G.; Zhao, X.; et al. Targeting lipid metabolism of macrophages: A new strategy for tumor therapy. J. Adv. Res. 2024, in press. [Google Scholar] [CrossRef]
- Saini, R.K.; Prasad, P.; Shang, X.; Keum, Y.-S. Advances in lipid extraction methods—A review. Int. J. Mol. Sci. 2021, 22, 13643. [Google Scholar] [CrossRef]
- Godet, I.; Doctorman, S.; Wu, F.; Gilkes, D.M. Detection of hypoxia in cancer models: Significance, challenges, and advances. Cells 2022, 11, 686. [Google Scholar] [CrossRef]
- Kong, X.; Zhang, Q.; Wu, X.; Zou, T.; Duan, J.; Song, S.; Nie, J.; Tao, C.; Tang, M.; Wang, M.; et al. Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Front. Oncol. 2022, 12, 816297. [Google Scholar] [CrossRef] [PubMed]
- Guo, Z.; Bergeron, K.-F.; Lingrand, M.; Mounier, C. Unveiling the MUFA-Cancer connection: Insights from endogenous and exogenous perspectives. Int. J. Mol. Sci. 2023, 24, 9921. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.; Das, D.; Taneja, R. Targeting Dysregulated Lipid Metabolism in Cancer with Pharmacological Inhibitors. Cancers 2024, 16, 1313. [Google Scholar] [CrossRef]
- Castellano, I.; Gallo, F.; Durelli, P.; Monge, T.; Fadda, M.; Metovic, J.; Cassoni, P.; Borella, F.; Raucci, C.; Menischetti, M.; et al. Impact of Caloric Restriction in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Prospective Case Control Study. Nutrients 2023, 15, 4677. [Google Scholar] [CrossRef]
- Camarda, R.; Zhou, A.Y.; Kohnz, R.A.; Balakrishnan, S.; Mahieu, C.; Anderton, B.; Eyob, H.; Kajimura, S.; Tward, A.; Krings, G.; et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med. 2016, 22, 427–432. [Google Scholar] [CrossRef] [PubMed]
- Luo, X.; Cheng, C.; Tan, Z.; Li, N.; Tang, M.; Yang, L.; Cao, Y. Emerging roles of lipid metabolism in cancer metastasis. Mol. Cancer 2017, 16, 76. [Google Scholar] [CrossRef]
- Ribeiro, R.; Carvalho, M.J.; Goncalves, J.; Moreira, J.N. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Front. Mol. Biosci. 2022, 9, 903065. [Google Scholar] [CrossRef]
- Roché, H.; Fumoleau, P.; Spielmann, M.; Canon, J.-L.; Delozier, T.; Serin, D.; Symann, M.; Kerbrat, P.; Soulié, P.; Eichler, F.; et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J. Clin. Oncol. 2006, 24, 5664–5671. [Google Scholar] [CrossRef]
- Zaheed, M.; Wilcken, N.; Willson, M.L.; O’Connell, D.L.; Goodwin, A. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst. Rev. 2019, 2, CD012873. [Google Scholar] [CrossRef]
- Gianni, L.; Pienkowski, T.; Im, Y.-H.; Tseng, L.-M.; Liu, M.-C.; Lluch, A.; Starosławska, E.; de la Haba-Rodriguez, J.; Im, S.-A.; Pedrini, J.L.; et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016, 17, 791–800. [Google Scholar] [CrossRef] [PubMed]
- Liedtke, C.; Thill, M.; Jackisch, C.; Thomssen, C.; Müller, V.; Janni, W.; AGO Breast Committee. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017. Breast Care 2017, 12, 172–183. [Google Scholar] [CrossRef]
- Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991, 19, 403–410. [Google Scholar] [CrossRef] [PubMed]
- Ogston, K.N.; Miller, I.D.; Payne, S.; Hutcheon, A.W.; Sarkar, T.K.; Smith, I.; Schofield, A.; Heys, S.D. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 2003, 12, 320–327. [Google Scholar] [CrossRef] [PubMed]
- Bydder, M.; Girard, O.; Hamilton, G. Mapping the double bonds in triglycerides. Magn. Reson. Imaging 2011, 29, 1041–1046. [Google Scholar] [CrossRef]
- Peterson, P.; Månsson, S. Simultaneous quantification of fat content and fatty acid composition using MR imaging. Magn. Reson. Med. 2013, 69, 688–697. [Google Scholar] [CrossRef]
- Wu, J.; Li, B.; Sun, X.; Cao, G.; Rubin, D.L.; Napel, S.; Ikeda, D.M.; Kurian, A.W.; Li, R. Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. Radiology 2017, 285, 401–413. [Google Scholar] [CrossRef]
- Braman, N.; Prasanna, P.; Whitney, J.; Singh, S.; Beig, N.; Etesami, M.; Bates, D.D.B.; Gallagher, K.; Bloch, B.N.; Vulchi, M.; et al. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer. JAMA Netw. Open 2019, 2, e192561. [Google Scholar] [CrossRef]
Characteristic | All (n = 15) | Good Responders (n = 7) | Poor Responders (n = 8) | p-Value |
---|---|---|---|---|
Age | 51 (43–60) | 49 (38–56) | 52 (47–60) | NS |
Tumour size (mm, baseline) | 22 (18–25) | 23 (21–25) | 20 (16–25) | NS |
Nottingham Prognostic Index (NPI) | 5.24 (4.68–6.10) | 4.66 (4.03–5.05) | 5.90 (5.24–6.40) | NS |
Histology | ||||
Invasive ductal carcinoma | 15 | 7 | 8 | |
Grade | ||||
Grade II | 1 | 1 | 0 | |
Grade III | 14 | 6 | 8 | |
Hormonal receptor status | ||||
Oestrogen receptor positive (ER+) | 6 | 2 | 4 | |
Human epidermal growth factor receptor 2 positive (HER2+) | 2 | 2 | 0 | |
Triple negative (TN) | 7 | 3 | 4 |
Parameter | Percentage Change at Cycle1 (%) | Good vs. Poor a | Percentage Change CD163 b | NPI b | ||||
---|---|---|---|---|---|---|---|---|
All (n = 15) | Good Responder (n = 7) | Poor Responder (n = 8) | z Score, p Value | rs, p Value | 95% CI | rs, p Value | 95% CI | |
Peri-tumoural | ||||||||
MUFAs | 0.75 (−0.02–1.58) | 0.37 (−0.15–1.09) | 0.91 (0.19–2.46) | 0.96, 0.336 | 0.59, 0.021 * | (0.11, 0.85) | −0.09, 0.790 | (−0.66, 0.54) |
PUFAs | 4.34 (−0.06–8.12) | 2.03 (−0.55–5.77) | 6.13 (0.99–11.00) | 0.96, 0.336 | 0.57, 0.027 * | (0.08, 0.84) | −0.05, 0.873 | (−0.63, 0.56) |
SFAs | −1.89 (−2.61–0.03) | −0.94 (−2.61–0.20) | −1.98 (−2.43–−0.49) | 0.06, 0.955 | −0.26, 0.354 | (−0.68, 0.29) | −0.09, 0.790 | (−0.66, 0.54) |
R2* | −6.62 (−12.32–0.83) | −3.88 (−8.25–3.15) | −10.07 (−14.01–−6.37) | 1.31, 0.189 | −0.50, 0.056 | (−0.81, 0.01) | −0.18, 0.593 | (−0.70, 0.47) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cheung, S.M.; Chan, K.-S.; Senn, N.; Husain, E.; Sharma, R.; McGoldrick, T.; Gagliardi, T.; Masannat, Y.; He, J. Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer. Int. J. Mol. Sci. 2024, 25, 9303. https://doi.org/10.3390/ijms25179303
Cheung SM, Chan K-S, Senn N, Husain E, Sharma R, McGoldrick T, Gagliardi T, Masannat Y, He J. Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer. International Journal of Molecular Sciences. 2024; 25(17):9303. https://doi.org/10.3390/ijms25179303
Chicago/Turabian StyleCheung, Sai Man, Kwok-Shing Chan, Nicholas Senn, Ehab Husain, Ravi Sharma, Trevor McGoldrick, Tanja Gagliardi, Yazan Masannat, and Jiabao He. 2024. "Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer" International Journal of Molecular Sciences 25, no. 17: 9303. https://doi.org/10.3390/ijms25179303